Effect of ticagrelor on acute kidney injury in septic rats and its underlying mechanism
Related Experiment Video
Updated: Nov 11, 2025

Standardized Colon Ascendens Stent Peritonitis in Rats - a Simple, Feasible Animal Model to Induce Septic Acute Kidney Injury
Published on: February 15, 2022
Cheng Yu1, Cui-Min Gao1, Na Xie1
1Department of Anesthesiology, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Abstract:
The aim of the present study was to determine whether the effects and underlying mechanisms of ticagrelor in a rat model of sepsis-induced acute kidney injury (AKI) were mediated via the CD62P pathway. A total of 15 rats were randomly assigned to the following groups: Normal, sham, cecal ligation and puncture (CLP), CLP + clinical dose of ticagrelor (CCD) and CLP + loading dose of ticagrelor (CLD). Ticagrelor was administered 12 h before modeling, immediately after modeling, and 12 h after modeling at a dose of 8.6 and 46.42 mg/kg in the CCD and CLD groups, respectively. Rats in the normal, sham and CLP groups were treated with the same volume of distilled water. Serum creatinine (SCr), CD62P and interleukin-1β (IL-1β) levels, myeloperoxidase (MPO) activity in the renal tissue and the apoptosis rate of renal cells were increased in the CLP group, compared with in the normal and sham groups (P<0.05). In addition, ticagrelor treatment reduced SCr, CD62P and IL-1β expression levels, renal tissue MPO activity and renal cell apoptosis in rats with sepsis-induced AKI (P<0.05). CD62P expression was closely associated with the occurrence of sepsis-induced AKI. The mechanism of ticagrelor-mediated reductions in inflammation, renal neutrophil infiltration and renal cell apoptosis is possibly associated with reductions in CD62P expression.
Insights
Ticagrelor treatment effectively reduced kidney damage and inflammation in a rat model of sepsis-induced acute kidney injury (AKI). These protective effects are linked to the downregulation of the CD62P pathway, suggesting a novel therapeutic mechanism.
Area of Science:
- Nephrology
- Pharmacology
- Immunology
Background:
- Sepsis-induced acute kidney injury (AKI) is a critical complication with high mortality.
- The CD62P pathway plays a significant role in inflammatory responses and tissue damage during sepsis.
- Ticagrelor, an antiplatelet drug, has shown potential in various inflammatory conditions.
Purpose of the Study:
- To investigate the therapeutic effects of ticagrelor on sepsis-induced AKI in a rat model.
- To elucidate the underlying mechanisms, specifically the involvement of the CD62P pathway.
Main Methods:
- A rat model of sepsis-induced AKI was established using cecal ligation and puncture (CLP).
- Rats were treated with different doses of ticagrelor (clinical and loading doses) or distilled water.
- Key markers including serum creatinine, CD62P, interleukin-1β, myeloperoxidase activity, and renal cell apoptosis were assessed.
Main Results:
- CLP significantly increased serum creatinine, CD62P, IL-1β, myeloperoxidase activity, and renal cell apoptosis compared to normal and sham groups.
- Ticagrelor treatment significantly reduced these elevated markers in a dose-dependent manner.
- CD62P expression was found to be closely associated with the development of sepsis-induced AKI.
Conclusions:
- Ticagrelor demonstrates significant renoprotective effects in a rat model of sepsis-induced AKI.
- The mechanism of action involves the reduction of inflammation, neutrophil infiltration, and renal cell apoptosis.
- Downregulation of the CD62P pathway is a key mechanism underlying ticagrelor's therapeutic benefits in sepsis-induced AKI.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

